Rheumatoid Arthritis - Pipeline Review, H2 2016 - Key Vendors are A&G Pharmaceutica, Amgen, GlaxoSmithKline, Merck & Novartis - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Rheumatoid Arthritis - Pipeline Review, H2 2016" report to their offering.

Rheumatoid arthritis (RA) is an autoimmune chronic disorder that eventually leads to destruction of bones causing deformities. Signs and symptoms of rheumatoid arthritis include tender, warm, swollen joints, fatigue, and fever and weight loss. Rheumatoid arthritis may be a result of genetic and certain specific environmental factors. Women are much more susceptible to develop RA. Treatment includes non-steroidal anti-inflammatory drugs, corticosteroid medications and immunosuppressants.

This report provides comprehensive information on the therapeutic development for Rheumatoid arthritis (RA), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rheumatoid arthritis (RA) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Mentioned:

  • 3SBio Inc
  • 4D Pharma Plc
  • A&G Pharmaceutical Inc
  • AB Science SA
  • AB2 Bio Ltd
  • AbbVie Inc
  • Ablynx NV
  • ACEA Biosciences Inc
  • Addex Therapeutics Ltd
  • Adello Biologics LLC
  • Advinus Therapeutics Ltd
  • AlphaMab Co Ltd
  • Alteogen Inc
  • Amgen Inc
  • Amura Holdings Ltd
  • Anacor Pharmaceuticals Inc
  • AnGes MG Inc
  • Applied Genetic Technologies Corp
  • Aptevo Therapeutics Inc
  • ARA Healthcare Pvt Ltd
  • (200+ Others)

Key Topics Covered:

  1. Introduction
  2. Rheumatoid arthritis (RA) Overview
  3. Therapeutics Development
  4. Pipeline Products for Rheumatoid arthritis (RA) - Overview
  5. Pipeline Products for Rheumatoid arthritis (RA) - Comparative Analysis
  6. Rheumatoid arthritis (RA) - Therapeutics under Development by Companies
  7. Rheumatoid arthritis (RA) - Therapeutics under Investigation by Universities/Institutes
  8. Rheumatoid arthritis (RA) - Pipeline Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Rheumatoid arthritis (RA) - Products under Development by Companies
  13. Rheumatoid arthritis (RA) - Products under Investigation by Universities/Institutes
  14. Rheumatoid arthritis (RA) - Companies Involved in Therapeutics Development

For more information about this report visit http://www.researchandmarkets.com/research/nzlqb3/rheumatoid

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs, Musculoskeletal Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs, Musculoskeletal Disorders Drugs